21.87
price down icon9.89%   -2.40
after-market Handel nachbörslich: 21.93 0.06 +0.27%
loading
Schlusskurs vom Vortag:
$24.27
Offen:
$23.67
24-Stunden-Volumen:
2.39M
Relative Volume:
1.44
Marktkapitalisierung:
$2.78B
Einnahmen:
$715.22M
Nettoeinkommen (Verlust:
$-250.10M
KGV:
-10.77
EPS:
-2.03
Netto-Cashflow:
$-205.58M
1W Leistung:
-9.85%
1M Leistung:
-13.04%
6M Leistung:
-24.17%
1J Leistung:
-62.79%
1-Tages-Spanne:
Value
$21.70
$24.00
1-Wochen-Bereich:
Value
$21.70
$24.88
52-Wochen-Spanne:
Value
$21.70
$59.91

Apellis Pharmaceuticals Inc Stock (APLS) Company Profile

Name
Firmenname
Apellis Pharmaceuticals Inc
Name
Telefon
617-977-5700
Name
Adresse
100 FIFTH AVENUE, WALTHAM, KY
Name
Mitarbeiter
710
Name
Twitter
@ApellisPharma
Name
Nächster Verdiensttermin
2024-12-05
Name
Neueste SEC-Einreichungen
Name
APLS's Discussions on Twitter

Vergleichen Sie APLS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
APLS
Apellis Pharmaceuticals Inc
21.87 2.78B 715.22M -250.10M -205.58M -2.03
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-17 Herabstufung Goldman Buy → Neutral
2024-11-21 Eingeleitet Morgan Stanley Equal-Weight
2024-10-25 Eingeleitet RBC Capital Mkts Sector Perform
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-10-16 Eingeleitet William Blair Outperform
2024-05-31 Eingeleitet Piper Sandler Neutral
2024-02-05 Hochstufung Jefferies Hold → Buy
2023-12-14 Herabstufung Wells Fargo Overweight → Equal Weight
2023-11-09 Eingeleitet Goldman Buy
2023-11-02 Eingeleitet Mizuho Neutral
2023-10-06 Hochstufung JP Morgan Neutral → Overweight
2023-09-15 Hochstufung Wells Fargo Equal Weight → Overweight
2023-08-29 Bestätigt Citigroup Buy
2023-08-03 Herabstufung JP Morgan Overweight → Neutral
2023-08-01 Herabstufung BofA Securities Buy → Neutral
2023-01-03 Herabstufung Wells Fargo Overweight → Equal Weight
2022-11-10 Herabstufung Jefferies Buy → Hold
2022-07-19 Eingeleitet H.C. Wainwright Buy
2022-06-17 Fortgesetzt Stifel Buy
2022-04-14 Herabstufung ROTH Capital Neutral → Sell
2021-12-08 Eingeleitet Wells Fargo Overweight
2021-11-29 Herabstufung ROTH Capital Buy → Neutral
2021-09-10 Bestätigt BMO Capital Markets Outperform
2021-09-10 Bestätigt Credit Suisse Neutral
2021-09-10 Bestätigt Needham Buy
2021-09-10 Bestätigt Oppenheimer Outperform
2021-09-10 Herabstufung Wedbush Outperform → Neutral
2021-08-19 Eingeleitet Jefferies Buy
2021-08-19 Hochstufung Wedbush Neutral → Outperform
2021-05-21 Eingeleitet UBS Buy
2021-04-16 Eingeleitet Goldman Buy
2020-11-19 Eingeleitet Needham Buy
2020-09-01 Eingeleitet Stifel Buy
2020-07-20 Eingeleitet ROTH Capital Buy
2020-06-17 Eingeleitet BTIG Research Neutral
2020-04-01 Eingeleitet Raymond James Strong Buy
2020-03-31 Eingeleitet BMO Capital Markets Outperform
2020-03-11 Hochstufung Wedbush Underperform → Neutral
2020-01-07 Eingeleitet SVB Leerink Mkt Perform
2019-12-19 Eingeleitet BofA/Merrill Buy
2019-11-22 Eingeleitet Wedbush Underperform
2019-11-05 Eingeleitet Credit Suisse Neutral
2019-08-01 Bestätigt Cantor Fitzgerald Overweight
2019-07-12 Hochstufung JP Morgan Neutral → Overweight
2019-03-29 Eingeleitet Robert W. Baird Outperform
2019-01-23 Herabstufung JP Morgan Overweight → Neutral
2018-07-30 Hochstufung B. Riley FBR Neutral → Buy
2018-05-24 Eingeleitet Cantor Fitzgerald Overweight
2018-04-12 Herabstufung B. Riley FBR, Inc. Buy → Neutral
2018-02-08 Eingeleitet B. Riley FBR, Inc. Buy
Alle ansehen

Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten

pulisher
Mar 29, 2025

(APLS) Investment Analysis - news.stocktradersdaily.com

Mar 29, 2025
pulisher
Mar 26, 2025

Fierce Biotech Layoff Tracker 2025: Elevation eliminates 70% of staff; ElevateBio trims team - Fierce Biotech

Mar 26, 2025
pulisher
Mar 25, 2025

Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey

Mar 25, 2025
pulisher
Mar 25, 2025

Apellis Pharma stock hits 52-week low at $23.77 amid market challenges - Investing.com

Mar 25, 2025
pulisher
Mar 24, 2025

12 Most Promising Biotech Stocks According to Wall Street Analysts - Insider Monkey

Mar 24, 2025
pulisher
Mar 24, 2025

Apellis Pharmaceuticals chief development officer sells shares worth $39,279 - MSN

Mar 24, 2025
pulisher
Mar 21, 2025

Apellis Pharmaceuticals (APLS) Gets a Hold from Scotiabank - The Globe and Mail

Mar 21, 2025
pulisher
Mar 20, 2025

Cardurion Taps Apellis Veteran Who Led 450% Team Growth for Top HR Role - StockTitan

Mar 20, 2025
pulisher
Mar 19, 2025

University Retina Participate in Apellis Pharmaceuticals’ Groundbreaking Clinical Trials for SYFOVRE, the first and only FDA-approved treatment for Geographic Atrophy - Business Wire

Mar 19, 2025
pulisher
Mar 19, 2025

Apellis Pharmaceuticals CFO Timothy Sullivan sells $51,827 in stock - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

(APLS) Long Term Investment Analysis - news.stocktradersdaily.com

Mar 19, 2025
pulisher
Mar 18, 2025

Apellis Pharmaceuticals executive sells shares valued at $4,542 By Investing.com - Investing.com Australia

Mar 18, 2025
pulisher
Mar 18, 2025

JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Apellis Pharmaceuticals Beats Investor Suit Over Eye Drug Risks - Bloomberg Law News

Mar 18, 2025
pulisher
Mar 18, 2025

Apellis Pharmaceuticals executive sells shares valued at $4,542 - Investing.com India

Mar 18, 2025
pulisher
Mar 14, 2025

Apellis Pharmaceuticals (NASDAQ:APLS) Is Making Moderate Use Of Debt - Simply Wall St

Mar 14, 2025
pulisher
Mar 14, 2025

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Sold by Bank of New York Mellon Corp - Defense World

Mar 14, 2025
pulisher
Mar 12, 2025

Victory Capital Management Inc. Purchases 150,363 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Will Apellis Pharma's Empaveli Prove VALIANT In Battling Rare Kidney Diseases? - RTTNews

Mar 11, 2025
pulisher
Mar 08, 2025

Learn to Evaluate (APLS) using the Charts - news.stocktradersdaily.com

Mar 08, 2025
pulisher
Mar 07, 2025

Apellis Pharmaceuticals general counsel sells shares for $139,789 By Investing.com - Investing.com South Africa

Mar 07, 2025
pulisher
Mar 07, 2025

Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace

Mar 07, 2025
pulisher
Mar 06, 2025

Insider Sells Thousands of Apellis Pharmaceuticals Shares! - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Apellis Pharmaceuticals general counsel sells shares for $139,789 - Investing.com India

Mar 06, 2025
pulisher
Mar 06, 2025

Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics - MSN

Mar 06, 2025
pulisher
Mar 06, 2025

HC Wainwright Issues Pessimistic Forecast for APLS Earnings - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Wedbush Lifts Earnings Estimates for Apellis Pharmaceuticals - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst - Benzinga

Mar 06, 2025
pulisher
Mar 06, 2025

Wedbush Issues Optimistic Outlook for APLS Earnings - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

Apellis Pharmaceuticals: A Mixed Bag (NASDAQ:APLS) - Seeking Alpha

Mar 05, 2025
pulisher
Mar 05, 2025

UBS Adjusts Apellis Pharmaceuticals Price Target to $43 From $45, Maintains Buy Rating - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2024 Earnings Call Transcript - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

JPMorgan Chase & Co. Issues Positive Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Apellis Pharmaceuticals Faces Financial Challenges Amid Ambitious Drug Commercialization Efforts - MSN

Mar 04, 2025
pulisher
Mar 04, 2025

Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $29.00 by Analysts at Wedbush - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Apellis Pharmaceuticals’ (APLS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $32.00 at The Goldman Sachs Group - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $25.00 at Royal Bank of Canada - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Apellis Class Action: Levi & Korsinsky Reminds Apellis Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 2, 2023 – APLS - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

Breaking Down Apellis Pharmaceuticals: 6 Analysts Share Their Views - Benzinga

Mar 03, 2025
pulisher
Mar 03, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Apellis Pharmaceuticals, Inc.(APLS) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

New York State Common Retirement Fund Sells 327,776 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

Mar 03, 2025

Finanzdaten der Apellis Pharmaceuticals Inc-Aktie (APLS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Kapitalisierung:     |  Volumen (24h):